M28 Capital Management LP 4
4 · Adagio Therapeutics, Inc. · Filed Aug 19, 2022
Insider Transaction Report
Form 4
Elia Marc
DirectorOther
Transactions
- Purchase
Common Stock
2022-08-19$4.62/sh+584,451$2,700,164→ 9,248,250 total(indirect: See footnote) - Purchase
Common Stock
2022-08-18$4.31/sh+1,265,549$5,454,516→ 8,663,799 total(indirect: See footnote) - Purchase
Common Stock
2022-08-17$4.04/sh+1,000,000$4,040,000→ 7,398,250 total(indirect: See footnote)
Footnotes (5)
- [F1]The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $3.96 to $4.15.
- [F2]The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $3.90 to $4.50.
- [F3]The price in Column 4 is a weighted average purchase price. The prices actually paid ranged from $4.33 to $4.70.
- [F4]The reporting person undertakes to provide upon request by the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
- [F5]This Form 4 is filed by M28 Capital Management LP ("M28 Capital Management") and Marc Elia ("Mr. Elia") with respect to securities held by certain funds and accounts for which M28 Capital Management serves as investment manager. Mr. Elia is the Chief Investment Officer of M28 Capital Management and the Managing Member of M28 Capital Management GP LLC, the general partner of M28 Capital Management. Mr. Elia also serves on the Board of Directors of the Issuer. The Reporting Persons expressly disclaim beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein, if any.